ArticleTheranostics2022
Integrated analysis of circulating immune cellular and soluble mediators reveals specific COVID19 signatures at hospital admission with utility for prediction of clinical outcomes.
Article in Theranostics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- Distinct immunity dynamics of natural killer cells in mild and moderate COVID-19 cases during the Omicron variant phase.Frontiers in immunology · 2025Observational
- A20 as a Potential Therapeutic Target for COVID-19.Immunity, inflammation and disease · 2025Review
- Interferon Point Alteration in Hospitalized Patients with and Without COVID-19.Medical acupuncture · 2024Article
- Characterization model of the post COVID-19 condition based on immunological, biochemical, and cytokine markers.iScience · 2024Article
- Unravelling the cellular response to the SARS-COV-2 vaccine in inflammatory bowel disease patients on biologic drugs.Scientific reports · 2023Observational
- Multi-omic longitudinal study reveals immune correlates of clinical course among hospitalized COVID-19 patients.Cell reports. Medicine · 2023Article
- Alterations in the CD56International journal of molecular sciences · 2023Article
- Immunology of SARS-CoV-2 infection and vaccination.Clinica chimica acta; international journal of clinical chemistry · 2023Review
- COVIDanno, COVID-19 annotation in human.Frontiers in microbiology · 2023Article
- Article
- PD-1 is expressed in cytotoxic granules of NK cells and rapidly mobilized to the cell membrane following recognition of tumor cells.Oncoimmunology · 2022Article
- Mechanism of COVID-19-Related Proteins in Spinal Tuberculosis: Immune Dysregulation.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID19), caused by SARS-CoV-2, is a complex disease, with a variety of clinical manifestations ranging from asymptomatic infection or mild cold-like symptoms to more severe cases requiring hospitalization and critical care. The most severe presentations seem to be related with a delayed, deregulated immune response leading to exacerbated inflammation and organ damage with close similarities to sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.